Clinical Trials on Advanced Non-Small Cell Lung Cancer in New Zealand

Total 1879 results

Memorial Sloan Kettering Cancer Center

Recruiting

Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Genentech, Inc.

Completed

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Spain, France, United States, Taiwan, United Kingdom, Philippines, Latvia, Italy, Israel, Argentina, Mexico, Germany, Malaysia
Astellas Pharma Inc

Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NSCLC | Non Small Cell Lung Cancer

United States, Canada, Korea, Republic of, Singapore, Thailand, Hong Kong
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada
Genzyme, a Sanofi Company

Completed

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer (ZODIAC)

Lung Cancer | Non-small Cell Lung Cancer

Vietnam, United States, Brazil, France, Italy, Korea, Republic of, Mexico, Spain, Turkey, Germany, China, Japan, Netherlands, Argentina, Austria, Belgium, Canada, Portugal, Greece, India, Denmark, Malaysia, Indonesia, Thailand, Singapore
GlaxoSmithKline

Terminated

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Lung Cancer, Small Cell

United States
Obsidian Therapeutics, Inc.

Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Melanoma | Lung Cancer | Non Small Cell Lung Cancer | Metastatic Lung Cancer | Metastatic Melanoma | Metastatic Non Small Cell Lung Cancer | Tumor Skin

United States
Dartmouth-Hitchcock Medical Center

Completed

Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Montefiore Medical Center
Genentech, Inc.

Completed

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Non-Small Cell Lung Cancer

United States
Atlantic Health System

Terminated

Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Navire Pharma Inc., a BridgeBio company
Bristol-Myers Squibb

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Solid Tumor | Non Small Cell Lung Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Lung Cancer

United States
Roswell Park Cancer Institute

Completed

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, Spain, France, Belgium, Italy, Taiwan, Turkey
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer

United States
Genzyme, a Sanofi Company

Completed

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Non Small Cell Lung Cancer

United States, Australia, Brazil, France, Italy, Korea, Republic of, Mexico, Spain, United Kingdom, Philippines, China, Germany, Norway, Canada, Hong Kong, Argentina, Netherlands, Taiwan, India, Thailand, Indonesia, Denmark
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
SCRI Development Innovations, LLC
Sanofi; Genentech, Inc.

Completed

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Non-Small Cell Lung Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Novartis

Terminated

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United States
Columbia University
National Cancer Institute (NCI)

Terminated

Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET

Esophageal Cancer | Non-small Cell Lung Cancer

United States
Janssen Research & Development, LLC

Active, not recruiting

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

Non-Small-Cell Lung Cancer

United States, France, Taiwan, United Kingdom, China, Spain, Japan, Australia, Korea, Republic of, Canada
National Cancer Institute (NCI)

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Guam, Puerto Rico
University of Michigan Rogel Cancer Center

Active, not recruiting

Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease

Non-small Cell Lung Cancer

United States
BeiGene

Terminated

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

China, Australia
Summit Therapeutics
Akeso

Recruiting

Phase III Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

Canada, United States, Spain, Italy, France
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

Belgium, Australia, United States, Korea, Republic of, Spain, China, France, Germany, Thailand, Brazil, Japan, Hong Kong, Austria, Greece, Switzerland, Netherlands, Romania, Hungary, Italy, Chile, Taiwan, Poland, Canada, Argentina, Turkey
Genentech, Inc.

Completed

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Non-Small Cell Lung Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, Brazil, Korea, Republic of, Spain, Argentina, United States, Costa Rica, Chile, Latvia, Finland, Italy, Poland
University of Cologne
Charite University, Berlin, Germany; University Hospital, Essen; University Medicine... and other collaborators

Recruiting

Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) (DigiNet)

Non-small Cell Lung Cancer Stage IV

Germany
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
Summit Therapeutics
Akeso

Recruiting

Phase 3 Clinical Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

United States, Spain, China, France, Canada, Italy
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Non-small Cell Lung Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Estonia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, U... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; Nova...

Completed

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
Compass Therapeutics
Iqvia Pty Ltd; Merck, Sharp & Dohme, LLC, Rahway, NJ USA

Recruiting

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Melanoma | Head and Neck Cancer | Small Cell Lung Cancer | Metastatic Cancer | Mesothelioma | Non-small Cell Lung Cancer | Locally Advanced Solid Tumor

United States
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

United States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
Eli Lilly and Company

Completed

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer Stage IV

United States, Italy, Spain, Australia, France, Germany, Hungary, Korea, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

United States
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Australia, Taiwan, Brazil, Japan, Argentina
Jonsson Comprehensive Cancer Center
Pharmacia

Completed

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Lung Cancer

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, France, Korea, Republic of, Italy, Austria, China, Georgia, Greece, Ireland, Lithuania, Malaysia, Poland, Romania, Russian Federation, Slovakia, Thailand, Turkey, Ukraine
National Cancer Institute (NCI)

Terminated

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

HIV Infection | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors

United States, Korea, Republic of, Spain, United Kingdom, Brazil, Israel, New Zealand, Netherlands, Canada, Australia, Switzerland, Belgium, Italy, Norway, Poland, Hungary, Kenya, Russian Federation, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Spain, Hong Kong, Argentina, China, Netherlands, France, Brazil, Belgium, Canada, Germany, Greece, Italy, Japan, Turkey, Ukraine
Hanmi Pharmaceutical Company Limited

Terminated

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Non Small Cell Lung Cancer

United States, Australia, Italy, Korea, Republic of, Spain, Germany, Malaysia, Taiwan, Canada, Philippines

Clinical Trials on Advanced Non-Small Cell Lung Cancer in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations